Jefferies maintained a Buy on Lantheus and raised its price target to $110 on March 17, 2026, the headline move in the latest LNTH analyst rating updates. The same day William Blair also maintained Outperform, citing optimism the company will secure approval despite a PDUFA extension. Both actions keep analyst sentiment positive while shares have dropped 5.72% since the announcements. This LNTH analyst rating snapshot captures the firms, dates, price target, and immediate market reaction to guide investor decisions.
Snapshot of recent LNTH analyst rating changes
On March 17, 2026, Jefferies maintained Buy and raised its price target to $110. On the same date William Blair maintained Outperform, citing optimism on approval after a PDUFA extension. Both moves were recorded in StreetInsider coverage and reflect two notable firms keeping positive ratings for Lantheus.
Jefferies action and LNTH analyst rating implications
Jefferies’ decision to hold Buy and lift the PT to $110 signals confidence in Lantheus’ growth and pipeline value. For investors, a higher target with a maintained buy suggests analysts expect upside from pending approvals. The Jefferies note is reported here.
William Blair view and LNTH analyst rating after PDUFA delay
William Blair maintained Outperform on March 17, 2026, stressing optimism the company will secure approval despite the PDUFA extension. That firm frames the extension as a timing issue, not a substantive denial, which supports continued positive expectations. See the William Blair commentary here.
What the LNTH analyst rating updates mean for investors
A maintained Buy or Outperform means analysts see expected upside relative to peers. Investors should weigh that optimism against the 5.72% intraday decline reported after the notices. Ratings reflect projected fundamentals and catalyst timing, not guarantees, so risk management remains essential.
Historical context of LNTH analyst rating coverage
Lantheus has seen regular coverage from firms like Jefferies and William Blair. These March 17, 2026 notes continue a trend of positive analyst views amid product approval events. The two recorded actions are maintenance moves, not new downgrades, indicating steady analyst conviction.
Market impact, price moves, and LNTH analyst rating signals
The market cap sits at $4,938,032,134 and the company saw a -5.72% share move after the updates. Maintained positive ratings with a raised PT can stabilize sentiment, but headlines tied to regulatory timing can keep volatility high. Meyka AI rates LNTH with a grade of A.
Final Thoughts
Analyst notes on March 17, 2026 leave a clear message: major firms still favor Lantheus. Jefferies held Buy and lifted its price target to $110, while William Blair kept Outperform and flagged optimism on approval after a PDUFA extension. For investors, these maintained positive LNTH analyst rating calls suggest belief in long term upside, but they do not remove near-term regulatory and market risks. The stock fell 5.72% after the updates, showing how sentiment and timing affect price action. Meyka AI rates LNTH with a grade of A. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use these ratings as part of a broader research process and consult advisors before trading.
FAQs
What did Jefferies change in its LNTH analyst rating on March 17, 2026?
Jefferies maintained a Buy rating and raised its price target to $110 on March 17, 2026. The move keeps a positive LNTH analyst rating and signals expected upside from approvals and pipeline value.
What did William Blair say in its LNTH analyst rating note?
William Blair maintained Outperform on March 17, 2026, and said it is optimistic Lantheus will receive approval despite a PDUFA extension. The commentary supports a positive LNTH analyst rating view.
How should investors interpret these LNTH analyst rating actions?
Maintained Buy and Outperform ratings signal analyst confidence, but they are not guarantees. Investors should weigh the positive LNTH analyst rating against regulatory timing, recent -5.72% price reaction, and individual risk tolerance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)